A5025546732- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Acute Lymphoblastic Leukemia research
- Histone Deacetylase Inhibitors Research
- Chronic Myeloid Leukemia Treatments
- Immunodeficiency and Autoimmune Disorders
- Protein Degradation and Inhibitors
- Chronic Lymphocytic Leukemia Research
- Hemoglobinopathies and Related Disorders
- Multiple Myeloma Research and Treatments
- Palliative Care and End-of-Life Issues
- Childhood Cancer Survivors' Quality of Life
- Blood disorders and treatments
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Epigenetics and DNA Methylation
- Retinoids in leukemia and cellular processes
- Parvovirus B19 Infection Studies
- Advanced biosensing and bioanalysis techniques
- Eosinophilic Disorders and Syndromes
- RNA modifications and cancer
- Genomics and Rare Diseases
- Genomic variations and chromosomal abnormalities
- Chromatin Remodeling and Cancer
- Autoimmune and Inflammatory Disorders Research
Centre Hospitalier Universitaire de Lille
2019-2025
Centre National de la Recherche Scientifique
2020-2025
Université de Lille
2017-2025
Inserm
2017-2025
Lille’s Cardiology Hospital
2019-2024
Institut pour la Recherche sur le Cancer de Lille
2019-2024
CANTHER - Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers
2020-2024
Institut de Biologie de Lille
2019-2024
Miniaturisation pour la Synthèse, l'Analyse et la Protéomique
2022
European Organisation for Research and Treatment of Cancer
2019-2020
Abstract Despite recent refinements in the diagnostic and prognostic assessment of CEBPA mutations AML, several questions remain open, i.e. implications different types basic region leucin zipper (bZIP) mutations, role co-mutations allelic state. Using pooled primary data analysis on 1010 -mutant adult AML patients, a comparison was performed taking into account type mutation (bZIP: either typical in-frame insertion/deletion (InDel) (bZIP InDel ), frameshift or nonsense inducing...
The detection of somatic mutations among the genes myeloid cells in asymptomatic patients-defining clonal haematopoiesis indeterminate potential (CHIP)-is associated with a predisposition to cardiovascular events (CVEs) general population. We aimed determine whether CHIP was CVEs SLE patients.The study is an ancillary randomized, double-blind, placebo-controlled, multicentre PLUS trial conducted from June 2007 through August 2010 at 37 centres France, involving 573 patients. search for by...
Abstract Tandem duplications (TDs) of the UBTF gene have been recently described as a recurrent alteration in pediatric acute myeloid leukemia (AML). Here, by screening 1946 newly diagnosed adult AML, we found that -TDs occur about 3% patients aged 18–60 years, mutually exclusive pattern with other known AML subtype-defining alterations. The characteristics 59 adults -TD included young age (median 37 years), low bone marrow (BM) blast infiltration 25%), and high rates WT1 mutations (61%),...
We investigated using a custom NGS panel of 149 genes the mutational landscape 64 consecutive adult patients with tyrosine kinase fusion-negative hypereosinophilia (HE)/hypereosinophilic syndrome (HES) harboring features suggestive myeloid neoplasm. At least one mutation was reported in 50/64 (78%) (compared to 8/44 (18%) idiopathic HE/HES/HE
Haematology is a speciality frequently confronted with end-of-life situations, and teams will be concerned by the question of medical assistance in dying. The Ethics Commission French Society has conducted survey on knowledge perceptions healthcare professionals regarding complex situations. A cross-sectionalonline hematology France. comprehensive online questionnaire addressed respondents' experience situations hematology, based 7 clinical vignettes. contained 55 questions, 6 which were...
Microtransplantation is a cellular therapy used in acute myeloid leukaemia and myelodysplastic syndromes as maintenance patients ineligible for regular allogeneic stem cell transplantation. We performed monocentric retrospective study of leukaemia, syndromes, chronic myelomonocytic who underwent microtransplantations at Nice University Hospital. analysed the evolution disease mutational status after microtransplantation. report 18 microtransplantation courses, with total 47 between February...
Deletions and partial losses of chromosome 7 (chr7) are frequent in acute myeloid leukemia (AML) linked to dismal outcome. However, the genomic landscape prognostic impact concomitant genetic aberrations remain incompletely understood.
Abstract Whether the LSC17 gene expression can improve risk stratification in context of next generation sequencing–based and measurable residual disease (MRD) patients with intensively treated AML has not been explored. We analyzed 504 adult prospectively ALFA-0702 trial. RUNX1 or TP53 mutations were associated higher LSC1 scores while CEBPA NPM1 lower scores. Patients high had a rate complete response (CR) multivariable analysis (odds ratio, 0.41; P = .0007), accounting for European...
Abstract Background of the study AML classification tools have been developed to stratify risk at diagnosis. There is a need evaluate these in current therapeutic era. Cohort characteristics In this retrospective study, we compared five classifiers: ELN 2017, 2022, ALFA classifier, Papaemmanuil et al. and Lindsley real‐life cohort 281 patients newly diagnosed for Nice University Hospital. our median age was 68 years old, sex ratio M/F 56%/44%, performance status lower than 2 73.1% patients,...
Abstract The evaluation of measurable residual disease (MRD) in acute myeloid leukemia (AML) using comprehensive mutation analysis by next-generation sequencing (NGS) has been investigated several studies. However controversial results exist regarding the detection persisting mutations DNMT3A , TET2 and ASXL1 (DTA). Benchmarking NGS-MRD taking into account other molecular MRD strategies to be done. Here, we performed error-corrected-NGS-MRD 189 patients homogeneously treated ALFA-0702 study...
Germline pathogenic variants in transcription factors predisposing
Over the past 2 decades, it has become evident that a significant proportion of acute myeloid leukemia (AML) occurs on background predisposing germline aberrations. The diagnosis these disorders is clinical interest as may imply specific management AML patients, especially for selection intrafamilial hematopoietic stem cell (HSC) donors, well genetic counseling and/or surveillance in other family members. However, determination an underlying predisposition remains challenging1-3 and not...